Pamrevlumab

Pamrevlumab

Status

Phase ||

Therapeutic Approach

Combating Fibrosis

Pamrevlumab (FG-3019) targets connective tissue growth factor (CTGF), which promotes muscle fibrosis and reduces the ability of damaged muscle cells to repair. Pamrevlumab binds to CTGF and may prevent this cascade. It it thought that treatment with pamrevlumab may slow the loss of muscle function.

Status

A Phase 2 trial is active, but no longer recruiting.

Sponsor

This program is sponsored by FibroGen, Inc.

Related Studies

ONGOING
Phase 2 study of Pamrevlumab (FG-3019) in people with Duchenne

Media Library

JUNE 2019
FibroGen Presents at the PPMD 2019 Annual Conference
JUNE 2018
FibroGen Presents at the PPMD 2018 Annual Conference
OCTOBER 2017
Webinar: FibroGen Update on Pamrevlumab & Enrolling Non-Ambulatory Study
PPMD and FibroGen hosted a webinar on October 25, 2017 to hear a community update on FibroGen’s development of Pamrevlumab and enrolling FGCL-3019-079 non-ambulatory study in Duchenne.
FEBRUARY 2017
Webinar: Mission DMD: FibroGen’s Anti-Fibrosis Program
On February 1, 2017, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is being conducted to investigate Pamrevlumab in Duchenne.

Join Our Mailing List